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Our previous study suggested that ceramide synthase 6
(CerS6), an enzyme in sphingolipid biosynthesis, is regulated by
p53: CerS6 was elevated in several cell lines in response to tran-
sient expression of p53 or in response to folate stress, which is
known to activate p53. It was not clear, however, whetherCerS6
gene is a direct transcriptional target of p53 or whether this was
an indirect effect through additional regulatory factors. In the
present study, we have shown that the CerS6 promoter is acti-
vated by p53 in luciferase assays, whereas transcriptionally inac-
tive R175H p53 mutant failed to induce the luciferase expres-
sion from this promoter. In vitro immunoprecipitation assays
and gel shift analyses have further demonstrated that purified
p53 binds within the CerS6 promoter sequence spanning 91 bp
upstream and 60 bp downstream of the transcription start site.
The Promo 3.0.2 online tool for the prediction of transcription
factor binding sites indicated the presence of numerous putative
non-canonical p53 bindingmotifs in theCerS6 promoter. Lucif-
erase assays and gel shift analysis have identified a single motif
upstream of the transcription start as a key p53 response ele-
ment. Treatment of cells with Nutlin-3 or low concentrations of
actinomycin D resulted in a strong elevation of CerS6 mRNA
and protein, thus demonstrating that CerS6 is a component of
the non-genotoxic p53-dependent cellular stress response. This
study has shown that by direct transcriptional activation of
CerS6, p53 can regulate specific ceramide biosynthesis, which
contributes to the pro-apoptotic cellular response.
The tumor suppressor p53 is a transcription factor com-
monly activated upon certain types of cellular stress such as
DNA damage, nutrient starvation, ribosomal stress, or onco-
genic signaling (1–4). The list of p53-regulated targets includes
several hundred genes (5), and the overall cellular response to
p53 activation is an integral function determined by differential
activation of target genes (6). Not all p53-responsive genes are
direct transcriptional targets of p53, and indirect effects of the
protein on transcription through other transcription factors or
additional regulatory elements are common (7, 8). For example,
one of the mechanismsmultiplying the number of p53-respon-
sive targets is the regulation of non-coding RNA transcription
(9). A bioinformatics approach predicted that p53 is likely to
regulate a handful ofmicroRNAs, which in turn control expres-
sion of hundreds of genes (10), a phenomenon dramatically
expanding the p53 network. The number of genes directly reg-
ulated by p53, however, could bemuch lower within a couple of
hundred targets (11). Furthermore, although initially p53 was
thought to act as the transcription activator, later it was dem-
onstrated that it can also repress transcription through direct
interaction with target genes as well as through indirect mech-
anisms (1, 3, 8). The direct transcriptional regulation by p53
itself is a complex process that could be affected by p53 modi-
fications, the interaction with p53 co-regulators, and coopera-
tion with other transcription factors (6).
Whether a given promoter is regulated by p53 depends on
the amount of the protein, its modification state, the cofactors
present at the promoter, or additional cooperating factors that
enhance or repress the p53-induced transcription (12). These
factors can also dictate which genes are targeted for transcrip-
tional regulation (2, 7). However, the most important compo-
nents defining the p53-directed transcriptional regulation are
the p53 response elements on the DNA (13). The sequence-
specific DNA binding activity of p53 is critical to its tumor
suppressor activity in response to cellular and environmental
stresses. Canonically, p53 binds as a tetramer to two decameric
motifs, which have been defined by the consensus sequence
RRRCWWGYYY with a separation of 0–13 bp, where R 
purine, Y pyrimidine, and W A or T (14). Further studies
have identified numerous non-canonical DNA binding motifs
for p53 that can differ significantly in their affinity to the pro-
tein (2). For example, it has been demonstrated that a 10-base
motif representing half of the canonical site can function as the
p53 response element (15). Furthermore, most of the validated
response elements have mismatches compared with the origi-
nally defined consensus motif, with 10% of such elements hav-
ing novel sequences not clearly related to the consensus motif
(2). Of note, functional activities of such non-canonical
response elements can vary significantly, with lower activity
sites requiring much higher levels of p53 protein for the tran-
scriptional regulation (2).
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Because p53 regulates transcription of so many genes
involved in a variety of cellular processes, the protein has a very
broad spectrum of its effect on cellular homeostasis. Pathways
regulated by p53 include DNA repair, cell cycle arrest, apopto-
sis, senescence, autophagy, angiogenesis, and migration (1–4).
More recently, the p53-dependent regulation of cellularmetab-
olism has been also underscored (4). Thus, p53 regulates both
glycolysis and oxidative phosphorylation shifting the energy
production to the latter pathway (16, 17). Such regulation is
achieved through the transcriptional repression of glucose
transporters type 1, 3, and 4 and transcriptional activation of
TIGAR, SCO2, GLS2, and Parkin (18–24). P53 also plays a key
role in lipid metabolism activating fatty acid oxidation and
inhibiting fatty acid synthesis (16), and it was further implicated
in the regulation of sphingolipid metabolism (25). Sphingolip-
ids play an important role in both the structural integrity of
cellular membranes and as signaling molecules involved in the
regulation of major cellular processes such as senescence, sur-
vival, and death (26, 27). Our previous study suggested that one
of the enzymes in sphingolipid biosynthesis, ceramide synthase
6 (CerS6),4 is regulated by p53 (28). Thus, CerS6was elevated in
several cell lines in response to transient expression of p53 and
also in response to folate stress, which is known to activate p53
(29, 30). For example, CerS6 was strongly elevated in response
to the antifolatemethotrexate in a p53-dependentmanner (31).
It was not clear, though, whether CerS6 gene is a direct tran-
scriptional target of p53 or this was an indirect effect through
additional regulatory factors. In the present study, we have
investigatedCerS6promoter as a direct transcriptional target of
p53.
Results
The CerS6 Promoter Is Regulated by p53—We have studied
the effect of p53 on theCerS6 promoter regulation using a lucif-
erase assay. The promoter has been previously cloned into
pGL3 vector bearing firefly luciferase cDNA (32), and this con-
struct was co-transfected with the p53-expressing vector in
A549 cells. By itself, theCerS6 promoter displayed a weak tran-
scriptional activity (Fig. 1A). However, we have observed a sig-
nificant (10-fold) increase in the luciferase activity in cells
co-transfected for the p53 expression compared with cells co-
transfected with the “empty” (negative control) plasmid (Fig.
1A). When cells were co-transfected with the luciferase-ex-
pressing reporter and the vector expressing the transcription-
ally deficient R175H p53 mutant, no increase in the luciferase
activity was recorded (Fig. 1A). To eliminate potential impact
from endogenous p53 protein onCerS6 promoter, we have also
performed luciferase assays in the p53-deficient A549 cell line.
In this cell line p53 was silenced by the stable expression of the
p53 shRNA, which completely prevented the protein expres-
sion (28, 33). Similar to p53-proficient A549 cells, strong acti-
vation of luciferase was seen in the p53-deficient cells upon
co-expression with the p53-expressing vector but not the vec-
tor expressingmutant p53 (Fig. 1B). Of note, levels of expressed
wild type andmutant p53were similar in each cell line (Fig. 1,A
and B, insets). Because the effect on the CerS6 promoter was
comparable in both cell lines, in further studies we used regular
A549 cells, which allow the evaluation of stress stimuli on the
CerS6 expression.
Previous study used four different length constructs of the
CerS6 promoter to explore its regulation (32), and we tested
these constructs for activation by p53. Luciferase assays have
shown that all four promoter constructs resulted in a strong
increase of luciferase activity when co-transfected with the p53
expression vector (Fig. 1C). Of note, the shortest construct was
most active in the presence of p53 (Fig. 1C).
Identification of the p53 Binding Motif in the CerS6
Promoter—A previously published study of CerS6 promoter
indicated its regulation by AP2, SP1/3, and CREB transcription
factors but not by p53 (32). Our analysis of CerS6 promoter
4 The abbreviations used are: CerS6, ceramide synthase 6; RE, response
element.
FIGURE 1. CerS6 promoter is activated by p53. A, activity of the CerS6 pro-
moter in A549 cells with and without expressed p53, assessed as the relative
luminescence units (RLU) in luciferase reporter assays. Co-transfections of
CerS6 luciferase reporter with empty vector (EV), vector expressing wild type
(wt) p53, or vector expressing the transcriptionally deficient R175H mutant
were carried out, and luciferase activitywasmeasured 48 h post-transfection.
B, same as A, but experiments were performed in A549 p53 shRNA (p53/)
cells. A reporter construct with the 1625-bp full-length (FL) promoter was
used in experiments depicted in A and B; basic plasmid (BP, the pGL3 lucifer-
ase vector without the CerS6 promoter) served as a negative control. Insets
show levels of p53 48 hpost-transfection (Western blotting assays).C, activity
of truncated CerS6 promoters measured in A549 cells by luciferase assays.
Reporter constructs were co-transfected with either empty vector or p53-
expressing vector. The diagramon the top schematically depicts the design of
CerS6 promoter constructs used in these experiments. In each panel the
means S.D. of a representative experiment performed in quadruplicate are
shown. Experiments were repeated at least three times.
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using several web-based tools for the prediction of transcrip-
tion factor binding sites, including Patch 1, Match, Matrix
Catch, Alibaba, and Transfac, did not produce hits correspond-
ing to the p53 binding motifs. Thus, it appeared that this pro-
moter does not have canonical p53-binding sites. Here we have
applied Promo 3.0.2 online tool (34, 35) for additional analysis
of the CerS6 promoter region, which included 1395 bp
upstreamof the transcription start and 284 bp of exon 1 (Fig. 2).
Surprisingly, in contrast to other tools, Promo 3.0.2 has indi-
cated multiple putative p53-binding sites in the CerS6 pro-
moter (Fig. 2). Most of the hits (27 of the total of 32 sites) are
located within of the proximal promoter (495 bp upstream of
the transcription start) and 200 bp of exon 1. Of note, some of
the predicted sites overlap within the same short contiguous
sequence, suggesting that the real number of such sites is lower
than the predicted number (Fig. 2).
Defining theMinimal CerS6 Promoter Responsive to p53—To
decipher themechanismof the activation ofCerS6 promoter by
p53, we created a set of truncated promoter constructs (Fig. 3).
The originally cloned CerS6 promoter included 1395 bp
upstreamof the transcription start site and a part of exon 1 (32).
The portion of exon 1 in the promoter consists of the entire
non-translatable (bp 1–200) and a part of translatable (bp 201–
284) region. This promoter structure defined our strategy in the
identification of the position of p53 response elements. By itself,
the promoter has a weak transcriptional activity that is
enhanced upon p53 expression by 6–10-fold (Fig. 3). The
removal of the translatable portion of exon 1 has improved the
response to p53 by 1.5-fold (Fig. 3). Whereas the precise
mechanism of this effect is not clear, further promoter bashing
was done with a construct lacking the translatable part of exon
1. Of note, the repressing effect of this translatable sequence on
the promoter activity in the presence of p53 was observed for
shorter promoter constructs as well; constructs III-V (Fig. 3)
had50% less activity if this portion of exon 1was not removed
(data not shown). Our experiments demonstrated that the p53
response elements are likely positioned in the CerS6 promoter
region extended from 291 to 50 bp (Fig. 3); this construct
revealed the strongest activation upon p53 expression, whereas
further truncation of the promoter beyond this region impaired
its activation by p53.
Purified p53 Binds the Essential CerS6 Promoter—The acti-
vation of CerS6 promoter by p53 in the luciferase assay can
proceed indirectly through regulatory elements activated by
p53. To investigate whether p53 directly binds to the essential
CerS6 promoter, we used the pulldown assay of the promoter
fragment (from 204 to 60 relative to the transcription start
site) on purified p53 protein. In these experiments the fragment
corresponding to the above promoter region was excised from
the plasmid using Sac1/HindIII endonucleases and purified
from agarose gel after electrophoresis. The fragment was fur-
ther incubated with full-length p53 protein and amplified by
PCR with specific primers after the pulldown on p53-specific
antibody and protein G-agarose (schematically depicted in Fig.
4A). Primers used for the amplification were fluorescently
labeled, allowing the direct detection of PCR fragments (primer
sequences are shown in Table 1). An intensive band corre-
sponding to the CerS6 promoter was observed after the pull-
down (Fig. 4B) that indicated the direct interaction between
p53 and the promoter. The specificity of this interaction was
demonstrated in control experiments, which used either
ALDH1L1 protein (36) instead of p53 and the corresponding
antibody or just IgG in the absence of p53; no amplified pro-
moter sequences were observed under these conditions (Fig.
4B, lanes 2 and 3, correspondingly). These experiments also
demonstrated that the interaction between p53 and the
sequence corresponding to the CerS6 promoter is very strong;
we were able to pull it down with p53 and its specific antibody
even in the absence of cross-linking (Fig. 4B, lane 4).
FIGURE 2. Analysis of the CerS6 promoter for the presence of p53-binding sites. Full-length CerS6 promoter sequence was analyzed using Promo 3.0.2
online tool. Putativep53 responseelements are shown in red; predictedbinding sites are indicatedbydouble-arrow lines. The transcription start site is indicated
by vertical arrow. The translation start in exon 1 (ATG) is shown in blue. The diagram on the top indicates positions of the putative p53 response elements (red
squares). Triangles indicate number of binding sites within a contiguous sequence.
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The interaction between essential CerS6 promoter and the
p53 protein was further confirmed by the gel-shift assays (Fig.
5). Six fragments corresponding to different promoter size and
generated by the PCR amplification were tested in these exper-
iments (Fig. 5A). Fluorescently labeled primers (Table 1) used
in these amplifications allowed the direct imaging of PCR prod-
ucts. Gel-shift assays have shown a strong size-specific shift of
the DNA in the presence of p53 for the four longest promoter
constructs, 151 to 355 bp, whereas no such shift was observed
for the two shortest constructs (Fig. 5B). A highmolecularmass
band was also seen for all pulled-down samples in the presence
of p53, indicating that this band was a result of nonspecific
aggregation (Fig. 5B). Additional nonspecific bands were
observed for the shortest construct (Fig. 5B). Overall, these
experiments have demonstrated that the essential CerS6 pro-
moter interacts with p53 and indicated that the p53-binding
site(s) is located within the 151-bp region extending from the
position 91 to the position 60 relative to the transcription
FIGURE 3.Activation of truncated CerS6 promoter constructs by p53. The schematic on the left depicts promoter constructs used in this study (violet blocks
correspond to the region upstream of the transcription start site; yellow blocks correspond to exon 1; the brown block in construct I indicates the translatable
part of exon 1; numbers indicate position of corresponding base pairs). Luciferase activity (mean S.D.) of three independent experiments (each in quadru-
plicate) is shown. BP, basic plasmid (promoterless reporter). RLU, relative luminescence units.
FIGURE 4. The p53 protein binds the essential CerS6 promoter. A, schematic depicting pulldown of CerS6 promoter fragment bound to p53 by immuno-
precipitation with p53-specific antibody (Ab). The fragment corresponding to 264-bp CerS6 promoter was excised from pGL3/CerS6 vector, incubated with
purified recombinant p53, cross-linked with formaldehyde, and pulled down using p53-specific antibody/protein G beads. After the pulldown, cross-linking
was reversedby5MNaCl. Thepulleddown sequencewas amplifiedbyPCRusing fluorescently labeled sequence-specific primers (shown in Table 1).B, agarose
gel electrophoresis of theamplifiedCerS6 fragment after thepulldown (asdepictedbypanel A). Lane1, pulldownof theCerS6promoterusing recombinantp53
andp53-specific antibody; lane 2, pulldownwithALDH1L1protein andALDH1L1-specific antibody; lane 3, pulldownwith human IgG; lane 4, sameas lane 1but
without cross-linking. The gel was stained with ethidium bromide, and the image was obtained using an Odyssey Fc instrument (LI-CORE). The green channel
was assigned to image the ethidiumbromide-staineddouble-strandedDNA; the red channel imaged the fluorescent primer. Double-strandedDNAcontaining
the fluorescent label was seen in yellow due to the two-channel overlay.
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FIGURE 5. Analysis of the binding of p53 to CerS6 promoter using gel shift assay. A, schematic depicting DNA fragments used in these experiments.
Fluorescent labeling of these fragments was achieved by the PCR amplification using primers with a covalently attached Cy5 fluorescent dye (Table 1).
B, gel shift analysis of the interaction between CerS6 promoter fragments (from panel A) and purified p53 (50 nM). Arrows indicate respective fragments
and DNA shifted upon the p53 binding. C, gel shift analysis of the interaction between the 151-bp promoter fragment (from panel A) and purified p53
(20–60 nM) in the presence or absence of p53-specific antibody (Ab). The last lane shows competition between the 151-bp fluorescent promoter
fragment and non-fluorescent double-stranded DNA containing the canonical p53-binding motif from p21 promoter (shown in Table 2) for the p53
binding (60 nM). C, negative control, no p53. D, gel shift analysis of the interaction between the 151-bp promoter fragment (from panel A) and increasing
concentrations of purified p53.
TABLE 1
Primers used for generation of CerS6 promoter constructs
Cy5 indicates fluorescent dye covalently attached to the 5 end of corresponding oligonucleotides.
Construct Primers Sequence
Reporters II-V Sense 5-CAAAGCAAGATTCGAGATCTGC-3
Antisense 5-GCAGATCTCGAATCTTGCTTTG-3
Reporter VI Sense 5-CGGCGGCGGCATCGAGATCTGC-3
Antisense 5-GCAGATCTCGATGCCGCCGCCG-3
Reporter VII Sense 5-GCGTTAGCCAGTGGGCGAGTTG-3
Antisense 5-CAACTCGCCCACTGGCTAACGC-3
Reporter VIII Sense 5-CTTCGAGAGCAGCGGCGGCGGCAC-3
Antisense 5-GTGCCGCCGCCGCTGCTCTCGAAG-3
Reporter IX Sense 5-CTTTCCCCAGTCGAGATCTG-3
Antisense 5-CAGATCTCGACTGGGGAAAG-3
Reporter X Sense 5-CCCTGCGGGCGTTCGAGATCTGCG-3
Antisense 5-CGCAGATCTCGAACGCCCGCAGGG-3
RE1 Sense 5-GACGAGCCAATCAGAGCTGCCATGTG-3
Antisense 5-CACATGGCAGCTCTGATTGGCTCGTC-3
RE2 Sense 5-GAGCTGCCATGTGATTTCCCCAGCGCGG-3
Antisense 5-CCGCGCTGGGGAAATCACATGGCAGCTC-3
RE1/2 Sense 5-GACGAGCCAATCATTTCCCCAGCGCG-3
Antisense 5-CGCGCTGGGGAAATGATTGGCTCGTC-3
RE3 Sense 5-GAGGAGAGAACCGCCGCGAGCCTTCG-3
Antisense 5-CGAAGGCTCGCGGCGGTTCTCTCCTC-3
355 bp Forward Cy5-GTTAGCCAGCATTCTGAGCATGTG-3
271 bp Forward Cy5-GCAAAGCGAAAGAGCGGTGAGAGC-3
190 bp Forward Cy5-GACTGCGCCCTGCCCTGC-3
151 bp Forward Cy5-GTGTGTGCCTCGCTGTTTGACGC-3
55 bp Forward Cy5-CAGAGGGAGGAGAGAACC
All Reverse Cy5-CTCGATGCCGCCGCCGCTGCTCTCG-3
39 bp Forward Cy5-GAGCCTTCGAGAGCAGCG-3
Reverse Cy5-CGCCGCCGCCTCCTCC
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start site. Gel shift experiments performed in the presence of
the p53-specific antibody resulted in the DNA supershift, fur-
ther confirming the p53-promoter interaction (Fig. 5C). This
interaction was disrupted in the presence of DNA duplex con-
taining a canonical p53-binding site from the p21 promoter
(Fig. 5C). The interaction of the 151-bp promoter with p53 as a
function of the protein concentration was further examined in
the gel shift assay, which indicated that the binding constant for
the interaction is20 nM (Fig. 5D).
The p53 Response Elements in the CerS6 Promoter—Based on
the results of the luciferase and gel-shift assays (above), we have
further focused on a shorter part of the promoter, from the
position 91 to the position 60. In this region three putative
p53 binding motifs have been identified (Fig. 6A). To study
whether the corresponding sequences are genuine p53
response elements (REs), we have created a set of promoter
constructs that retained all three motifs or its different combi-
nations (Fig. 6B) and tested them for the activation by p53 in
luciferase assays. These assays have shown that putative p53
response element 2 is a key for the activation ofCerS6 promoter
by p53; the promoter construct retaining RE2was as effective in
luciferase induction in response to p53 as the construct with all
three response elements, RE1–3 (Fig. 6C). Correspondingly, the
deletion of this putative response element decreased the acti-
vation by70% (Fig. 6C). Putative RE1 has shown some ability
to activate the promoter, although to a lower extent than RE2
(Fig. 6C). In contrast, putative RE3 was not involved in the p53
response; its deletion did not affect the luciferase activation,
and the construct retaining only RE3 was not induced by p53
(Fig. 6C). In agreement with the luciferase assay data, the gel-
shiftassaydemonstratedtheinteractionbetweentheshortoligo-
nucleotide bearing RE2 (Table 1) but not constructs bearing
RE1 or RE3 (Fig. 6D). The interactionwithRE2was disrupted in
the presence of DNA duplex containing a canonical p53-bind-
ing site from the p21 promoter (Fig. 6E).
CerS6 Transcription Is Induced upon p53 Activation—We
further investigated whether the p53 activation in the cell
induces the CerS6 promoter. One of the common ways to acti-
vate p53 is the treatment of cells with low concentrations of
actinomycin D (37). Treatment of A549 cells with 500 ng/ml
concentrations of the drug in our experiments resulted in ele-
vation of p53 protein, which was accompanied by strong
FIGURE 6.A single p53 response element upstreamof the transcription start site regulates CerS6 promoter. A, position of three predicted putative
p53 response elements in theminimal CerS6 promoter. The vertical arrow indicates the transcription start site; horizontal arrows correspond to duplexes
(Table 2) used for the gel shift assay in panels D and E. B, schematic depicting CerS6 promoter constructs with different combination of the p53 response
elements. C, activity of constructs (from panel B) with andwithout expressed p53, assessed as the relative luminescence units (RLU) in luciferase reporter
assays. Co-transfections of luciferase reporters with empty vector (Vector), vector expressing wild type p53 or vector expressing the transcriptionally
deficient R175H mutant were carried out, and luciferase activity was measured 48 h post-transfection. Luciferase activity (means S.D.) of a represen-
tative experiment performed in quadruplicate is shown. Experiments were repeated three times. FL, full length. D, gel shift analysis of the interaction
between duplexes corresponding to RE1–3 (Table 2) and varying concentrations of purified p53 (0–60 nM). E, competition for the p53 binding between
fluorescent RE2 duplex and non-fluorescent duplex containing the canonical p53-binding motif from p21 promoter (60 nM p53 was used; C, negative
control, no p53 added).
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increase in CerS6 mRNA and protein (Fig. 7A). To assure that
the elevation of CerS6 mRNAwas associated with the p53 acti-
vation andwas not a side effect of the drug,we also treatedA549
cells with Nutlin-3, a specific activator of the p53 pathway (38).
In agreement with the Nutlin-3 function, significant elevation
of the p53 protein was seen in cells exposed to 10 M concen-
trations of the drug (Fig. 7B). Similar to actinomycin D, Nut-
lin-3 has also evoked a strong increase in CerS6 mRNA, which
was accompanied by the increase in the CerS6 protein levels
(Fig. 7B).
Discussion
Ceramides, a group of sphingolipids, play an important role
as components of cellularmembranes (39–42) and as signaling
molecules (26, 43). In humans, there are six ceramide synthases,
CerS1–6, which are involved in biosynthesis of ceramide mol-
ecules with different acyl chain length (44, 45). Expression and
activity of these enzymes are regulated at several levels, includ-
ing transcription (46). The information on transcriptional reg-
ulation of ceramide synthases, however, is scarce. The analysis
of CerS1 and CerS6 promoters indicated their potential regula-
tion by several common transcription factors, with Sp1 playing
a key role in the activation of the CerS1 promoter (32). It has
been recently shown that two other ceramide synthase genes,
CerS4 andCerS5, are transcriptionally regulated by AP-1 in the
estrogen receptor-dependent manner (47). Although altera-
tions in biosynthesis and degradation of sphingolipids are asso-
ciated with the p53 activation, genes encoding enzymes of the
sphingolipid pathways, including ceramide synthases, are not
known as transcriptional targets of p53. It has been reported,
though, that p53 drives de novo ceramide synthesis by activat-
ing one of the ceramide synthases (48). Themechanism of such
activation could be indirect, through the p53 effect on addi-
tional transcription regulators or repressors. For example,
through the regulation ofmicroRNAsp53 can affect the expres-
sion of a plethora of genes (10). In fact, such regulation has been
shown for ceramide synthases: the alternative splice variant of
CerS1 is inhibited by microRNA-574-5p (32). Furthermore, it
has been recently reported that the elevation of CerS6 expres-
sion is associated with the reduction of microRNA-101 (49).
Interestingly, this microRNA was predicted to have p53
response elements (10). The co-regulation of p53 and CerS6
and the role of microRNAs in this process, however, are not so
clear. Thus, although CerS6 expression inversely correlates
with miR-101, a positive correlation between the p53 accumu-
lation and miR-101 has been recently reported (50). In this
mechanism, miR-101 targets the proteasome maturation pro-
tein POMP, leading to impaired proteasome assembly and
activity. So far there were no reports, which would specifically
study the transcriptional regulation of CerS genes by p53, but a
recent meta-analysis indicated the presence of p53 regulatory
elements in these genes, although corresponding target scores
were rather low (8).
We previously demonstrated that CerS6 is elevated in
response to p53 activation or upon transient transfection of p53
(28). Themechanismof such regulationwas not clear as the p53
binding motifs were not found in the CerS6 promoter region.
Toward this end, indirect regulation of gene expression by p53,
through the effect on other components of transcriptional
machinery, is a common phenomenon (7, 8). In fact, much
higher numbers of genes are indirect targets of p53 than its
direct transcriptional targets (5). Interestingly, we have previ-
ously identified a putative p53-binding site in the CerS6 gene
outside of the promoter region 3 kb downstream of the tran-
scription start site (28) though mechanisms that would allow
transcriptional regulation by utilizing such a remote site were
not clear. An implication of CerS6 (LASS6) as a potential tran-
scriptional target of p53 can be derived from the study, which
used ChIP with the paired-end di-tag sequencing to create a
global map of p53-binding sites in human genome (51). This
high throughput screen, while not specifically identifying the
CerS6 gene as one of the p53 targets, indicated a probability for
the presence of the p53-binding sites in proximity to the gene.
Despite the fact that the canonical p53-binding siteswere not
present in CerS6 promoter, in our studies the promoter was
strongly activated by p53 in luciferase reporter assays. This
finding prompted us to further search for p53 bindingmotifs in
theCerS6 promoter region. The Promo 3.0.2 online tool for the
prediction of transcription factor (TF) binding sites in DNA
sequences (34, 35) has identified multiple non-canonical p53-
binding sites upstream of the transcription start site and in the
non-translatable portion of exon 1. Although typically minimal
promoter includes the proximal sequence upstreamof the tran-
scription site, in the CerS6 promoter the part of exon 1 was
required for the full promoter activity. Of note, we have previ-
ously observed similar dependence for ALDH1L1 promoter
(52). Our study demonstrated that of numerous non-canonical
p53-binding sites in the CerS6 promoter; two upstream sites
most closely located to the transcription start are important for
FIGURE 7. Drugs activating p53 elevate levels of CerS6 mRNA and pro-
tein. A, effect of actinomycin D (ActD, 500 ng/ml) on CerS6 mRNA (left panel)
and protein (right panel) levels. B, effect of Nutlin-3 (10 M) on CerS6 mRNA
(left panel) and protein (right panel) levels. Error bars representS.D., n 3.
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the activation of the promoter by p53. This is in agreementwith
a general rule that the p53 response elements decrease their
transactivation potential as they are distanced from the tran-
scription start site (6, 11). Our data also indicate that one of
these sites is a key response element of p53 whereas the other
site might partially compensate for the absence of that key site.
Originally regarded as the regulator of the genotoxic stress
response, in recent years p53 has been established as a key
player inmetabolism regulation (4, 7, 16, 17). The identification
of novel p53 transcriptional targets involved in cellular metab-
olismprovides amore integrative viewof the effect ofmetabolic
stress on homeostasis maintenance. Metabolic pathways regu-
lated by p53 include glycolysis, oxidative phosphorylation, glu-
coneogenesis, serine biosynthesis, and fatty acid synthesis and
degradation (4, 7, 16, 17). Although some circuits in the meta-
bolic network are regulated by p53 indirectly, several key genes
involved in metabolic pathways are direct transcriptional tar-
gets of p53, including those encoding for glucose transporters
(23, 24), hexokinase 2 (53), mitochondrial glutaminase 2 (19,
20), carnitine palmitoyltransferase (54), pantothenate kinase-1
(55), phosphoglycerate dehydrogenase (56), and a component
of the cystine/glutamate antiporter (57). Our study extends the
p53 regulation to sphingolipid metabolism by demonstrating
that CerS6 is a bona fide p53 target gene. CerS6 satisfies all four
criteria for such genes (11): 1, it has p53 response elements in
the promoter; 2, its promoter binds p53, which was demon-
strated by several assays; 3, the promoter is activated by p53 in
the luciferase assay; 4, stress stimuli activating the p53 response
led to the elevation of CerS6. It is not clear at present whether
p53 requires other co-regulators to activate theCerS6promoter
or whether p53modifications (for example, phosphorylation at
different residues) affect the interaction with the response ele-
ments in the promoter. Our in vitro experiments, however,
indicated that non-modified p53 binds to the CerS6 promoter.
Interestingly, the transcriptional activation of CerS6 by p53
occurs in response to metabolic rather than genotoxic stress.
Thus, our previous study demonstrated that CerS6 is elevated
in a p53-dependent manner in response to folate stress enzyme
ALDH1L1 (28); ALDH1L1, however, induces p53 throughmet-
abolic alterations in the absence of DNA damage (33, 58). In
line with this finding, the treatment of cancer cells with antifo-
late methotrexate or folate withdrawal, two stimuli inducing
alterations in folate, amino acid, and nucleotide metabolism,
activated CerS6 in a p53-dependent fashion (28, 31). In the
present study the transcriptional induction of CerS6 by p53 in
the absence of genotoxic stress was further confirmed using
two canonical activators of p53, actinomycin D and Nutlin-3,
which do not induce DNA damage. Although actinomycin D at
higher concentrations activates p53 through the induction of
DNA damage (59), at low concentrations it mimics the effect of
Nutlin-3 (37). In our experiments treatment of cells with Nut-
lin-3 or low concentrations of actinomycin D resulted in a
strong elevation of both CerS6 mRNA and protein, thus dem-
onstrating that CerS6 is a component of the non-genotoxic
p53-dependent cellular stress response. It is still not fully
understood how the metabolic functions of p53 contribute to
its tumor suppression activity. Our present study has shown
that by transcriptional activation of CerS6, the enzyme in sph-
ingolipid metabolism, p53 can activate ceramide biosynthesis,
which contributes to the pro-apoptotic cellular response.
Experimental Procedures
Cell Culture and Reagents—Actinomycin D and other chem-
icals were purchased from Sigma unless otherwise indicated.
Nutlin-3 was obtained from Santa Cruz Biotechnology (Dallas,
TX). Cell culture media and reagents were from Invitrogen
ThermoFisher (Waltham,MA).A549 cell linewas fromATCC.
Generation of Truncated CerS6 Promoter Constructs—Trun-
cations of the promoter were carried out by the PCR-based
site-directedmutagenesis using PfuTurbo polymerase (Agilent
Technologies, Santa Clara, CA) as we previously described (52).
PCR primers (Table 1) were from Eurofins (Huntsville, AL). All
constructs were confirmed by sequencing.
Luciferase Reporter Assay—Reporter constructs were trans-
fected in A549 cells using Neon nucleofector (Invitrogen)
according to the manufacturer’s manual. Luminescence was
measured 48 h post-transfection using a Bright-Glo Luciferase
assay system (Promega, Durham, NC). The pGL3-Basic plas-
mid (promoter-less) was used in each experiment to determine
the basal levels of luciferase expression. Each construct was
tested in three independent transfection experiments. A dual
luciferase reporter assay system (Promega) was used to normal-
ize experiments for transfection efficiency (the pRL-TK plas-
mid expressing Renilla Luciferase was co-transfected with each
reporter vector at a ratio 1:10).
Expression and Purification of p53—The pCEP4-175 vector
was a generous gift from Dr. Jennifer Pietenpol. Vector for the
expression ofwild type p53was generated previously (33).Esch-
erichia coli BL21(DE3) cells transformed with P53 expression
construct were grown on an LB/ampicillin plate overnight. A
single colony was inoculated into 5 ml of LB medium contain-
ing 50g/ml ampicillin and grownovernight at 37 °C. Then 500
ml of LB medium with ampicillin were inoculated with the
overnight culture and incubated at 37 °C until A600 reached 0.7
followed by the addition of IPTG (1 mM final concentration,
Fisher) and incubated additionally for 12 h at 25 °C. Cells were
harvested by centrifugation (5000	 g, 10 min), resuspended in
50 ml of 50 mM NaH2PO4 buffer, pH 8.0, containing 300 mM
NaCl and incubated for 30 min with 1 mg/ml lysozyme at 4 °C.
The suspension was chilled on ice, sonicated, and spun down at
10,000	 g for 40 min). Supernatant was loaded on a PrepEase
nickel-nitrilotriacetic acid high yield agarose (USB Corp.)
column, and theHis-tagged protein was purified permanufacturer’s
instructions. Protein preparations obtained after metal-affinity
chromatographywere further subjected tosize-exclusionchroma-
tography on Sephacryl S300 (GEHealthcare).
Promoter Pulldown Assays—The fragment corresponding to
the promoter region 204 to 60 was excised from the pGL3/
CerS6 vector using SacI and HindIII restriction endonucleases
(both from New England BioLabs). The fragment was purified
by electrophoresis in agarose gel (2%)/gel extraction kit (Qia-
gen) and incubated with pure p53 (20 ng). The p53-DNA com-
plex was pulled down using p53-specific polyclonal antibody
(Santa Cruz, 1:200 dilution) and a CHIP assay kit (EZChiP kit,
Millipore). Theprocedurewas done according to themanufacturer’s
manual. Purified DNA was amplified by PCR using fluores-
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cently labeled primers (Table 1) and visualized using an Odys-
sey Fc imager (LI-COR Biosciences) after agarose gel electro-
phoresis. In the case of cross-linking, the p53-DNA complex
was treated with 1% formaldehyde, and the reversal of cross-
linking was done with 5 M NaCl.
Gel Shift Assay—Experimentswere performedwith synthetic
oligonucleotides or PCR-amplified fragments (Tables 1 and 2).
DNA and p53 were incubated in the reaction mixture contain-
ing 2 l of 10	 buffer (100 mM Tris, 500 mM KCl, 10 mM DTT,
pH 7.5), 1 l of poly(dIdC) (1 g/l in 10 mM Tris-HCl, 1 mM
EDTA, pH 7.5), 2 l of 25 mM DTT, 1 l of the corresponding
DNA (20 pmol/l) in 1	Tris-EDTAbuffer, 2l of purified p53
protein (5 ng/l in 20mMTris-HCl buffer, pH 7.5), and 12l of
H2O. Reaction mixtures were incubated for 30 min at room
temperature. Samples of DNA with or without pure p53
added were resolved using 4% native PAGE prepared in 50
mM Tris-HCl buffer, pH 7.5, 0.38 M glycine, and 2 mM
EDTA). In titration experiments, increasing concentrations
of p53 (2–60 nM) were used. The Kd was calculated accord-
ing fluorescence intensity of shifted DNA bands. For super-
shift experiments, DNA and p53 were incubated as above in
the presence of 1 or 2 g of p53-specific polyclonal antibody
(Santa Cruz), and the mixture was resolved using 3–8% gra-
dient polyacrylamide gels. Synthetic primers were purchased
from Eurofins. Longer promoter sequences were generated
by PCR amplification using pGL3/CerS6 vector and primers
shown in Table 1. The PCR mixture was resolved in 2% aga-
rose gel, and the amplified fragment was purified from the
gel using gel extraction kit (Qiagen).
Real Time PCR—Total RNA was purified using RNA Easy
Mini kit (Qiagen). Reverse transcriptase reaction was per-
formed with an oligo(dT)18 primer using Advantage™ RT-for-
PCR kit (Clontech). The resulting cDNA was used to measure
CerS6 mRNA levels using MyiQ™ Single-Color Real-time PCR
detection system (Bio-Rad) and the iQ5 optical system software
(Bio-Rad). CerS6 RT-quantitative PCR primers were: 5-GGG
ATC TTA GCC TGG TTC TGG-3 (forward), and 5-GCC
TCC GTG TTC TTC AG-3 (reverse). -Actin mRNA levels
were used to normalize samples.
Western Blotting Assays—Cell lysates for Western blotting
analysis were prepared in a buffer containing 50 mM Tris-HCl
(pH 8.0), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1%
SDS, 1 mM dithiothreitol, 1 mM PMSF, and protease inhibitor
mixture (Sigma). Samples were subjected to SDS-PAGE fol-
lowed by immunoblot with the corresponding antibodies.
CerS6 polyclonal antibodies (1:1000) were purchased from
Novus Biologicals (Littleton, CO). p53 was detected using
monoclonal antibody (clone Pab421, 1:500). Actinwas detected
using a monoclonal antibody from Sigma (clone AC-15,
1:5000).
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